Table 3.
Melanoma treatment by line of therapy
| Austria, Germany, UK (n = 35) n (%) |
Netherlands (n = 31) n (%) |
Total (N = 66) n (%) |
|
|---|---|---|---|
| First-line | 35 (100) | 31 (100) | 66 (100) |
| T-VEC monotherapy | 19 (54.3) | 29 (93.5) | 48 (72.7) |
| Chemotherapya | 5 (14.3) | 0 | 5 (7.6) |
| Ipilimumab monotherapy | 4 (11.4) | 0 | 4 (6.1) |
| Pembrolizumab monotherapy | 2 (5.7) | 2 (6.5) | 4 (6.1) |
| Ipilimumab + nivolumab combination therapy | 1 (2.9) | 0 | 1 (1.5) |
| Trametinib + dabrafenib combination therapy | 1 (2.9) | 0 | 1 (1.5) |
| Interleukin-2 monotherapy | 1 (2.9) | 0 | 1 (1.5) |
| Other systemic therapyb | 2 (5.7) | 0 | 2 (3.0) |
| Second-line | 17 (48.6) | 6 (19.4) | 23 (34.8) |
| T-VEC monotherapy | 6 (35.3) | 1 (16.7) | 7 (30.4) |
| Pembrolizumab monotherapy | 4 (23.5) | 3 (50.0) | 7 (30.4) |
| Ipilimumab monotherapy | 3 (17.6) | 0 | 3 (13.0) |
| Ipilimumab + nivolumab combination therapy | 1 (5.9) | 1 (16.7) | 2 (8.7) |
| Nivolumab monotherapy | 2 (11.8) | 0 | 2 (8.7) |
| Chemotherapya | 1 (5.9) | 0 | 1 (4.3) |
| Dabrafenib monotherapy | 0 | 1 (16.7) | 1 (4.3) |
| Other systemic therapyc | 0 | 2 (33.3) | 2 (8.7) |
| Third-line | 12 (34.3) | 1 (3.2) | 13 (19.7) |
| T-VEC monotherapy | 6 (50.0) | 1 (100) | 7 (53.8) |
| Pembrolizumab monotherapy | 2 (16.7) | 0 | 2 (15.4) |
| Chemotherapya | 1 (8.3) | 0 | 1 (7.7) |
| Ipilimumab + nivolumab combination therapy | 1 (8.3) | 0 | 1 (7.7) |
| Interleukin-2 monotherapy | 1 (8.3) | 0 | 1 (7.7) |
| Nivolumab monotherapy | 1 (8.3) | 0 | 1 (7.7) |
| Fourth-line | 7 (20.0) | 0 | 7 (10.6) |
| T-VEC monotherapy | 2 (28.6) | 0 | 2 (28.6) |
| Chemotherapya | 1 (14.3) | 0 | 1 (14.3) |
| Vemurafenib + cobimetinib combination therapy | 1 (14.3) | 0 | 1 (14.3) |
| Pembrolizumab monotherapy | 1 (14.3) | 0 | 1 (14.3) |
| Imatinib monotherapy | 1 (14.3) | 0 | 1 (14.3) |
| Trametinib monotherapy | 1 (14.3) | 0 | 1 (14.3) |
| Fifth-line | 4 (11.4) | 0 | 4 (6.1) |
| T-VEC monotherapy | 1 (25.0) | 0 | 1 (25.0) |
| Chemotherapya | 1 (25.0) | 0 | 1 (25.0) |
| Trametinib + dabrafenib combination therapy | 1 (25.0) | 0 | 1 (25.0) |
| Ipilimumab monotherapy | 1 (25.0) | 0 | 1 (25.0) |
| Sixth-line | 1 (2.9) | 0 | 1 (1.5) |
| Imatinib monotherapy | 1 (100) | 0 | 1 (100) |
| T-VEC monotherapy | 1 (100) | 0 | 1 (100) |
T-VEC talimogene laherparepvec
aExamples of chemotherapies given included dacarbazine, temozolomide, and taxanes
bOne patient received bevacizumab; the other participated in a clinical trial (NCT01844505)
cTwo patients participated in a clinical trial (NCT02625337)